Medication for treating CF

Vertex Begins Phase 3 Study of Kalydeco and VX-809

At the end of February 2013, Vertex Pharmaceuticals Inc. announced the initiation of international Phase 3 clinical trials of Kalydeco™ (formerly known as VX770) in combination with VX-809, a CF drug in development. Both Kalydeco and VX-809 are designed to treat…

FDA clears Novartis anti-bacterial inhaler for certain cystic fibrosis patients

Novartis TOBI Podhaler (tobramycin inhalation powder) 28mg per capsule has obtained FDA approval for the treatment of bacterial lung infection in certain cystic fibrosis (CF) patients. TOBI Podhaler is new non-nebulized formulation and delivery system of tobramycin that is indicated for…

Psychological challenges of living with CF

We all know how important it is to have a positive attitude in order to do as well as you can with CF. For me, one of the things that makes CF such a challenging condition is the fact that…

Information about Kalydeco and VX-809. Improvements in Lung Function

Improvements in Lung Function in F508del mutations - An update December 18, 2012 Victory as ground-breaking, Kalydeco gets funding go ahead in England The Cystic Fibrosis Trust has warmly welcomed the decision by the NHS to fund Kalydeco (ivacaftor) from 1 January 2013.…

Cystic Fibrosis Foundation Announces Agreement with Pfizer

Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, announced a major expansion of its research collaboration with Pfizer Inc. designed to discover new drugs to treat people with the most…

NICE Approves Pharmaxis’ Bronchitol® As An Important New Treatment Option for Cystic Fibrosis Patients

The European headquarters of Australian pharmaceutical company Pharmaxis (ASX: PXS) announced that the National Institute for Health and Clinical Excellence (NICE) has issued a positive recommendation in their Final Appraisal Determination (FAD) for Bronchitol® (mannitol dry powder for inhalation), licensed for the…

National Institute for Health and Clinical Excellence says yes for Novartis Tobi Podhaler

The National Institute for Health and Clinical Excellence has made draft recommendations for the treatment of lung infection in patients with cystic fibrosis (CF), and the news is good Novartis but not so good for Forest Laboratories. The cost regulator…

"Novartis TIP medicine is safe and effective" FDA advisers said

Drug advisers backed a new form of Novartis AG's inhaled antibiotic that treats a lung infection linked to cystic fibrosis A panel of outside advisers to the Food and Drug Administration voted 13 to 1 that Novartis had demonstrated that its…

Bronchitol - Q&A

On 18 October 2011, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Bronchitol 40 mg inhalation powder, hard capsules intended for the treatment of…

Oral and Intravenous Antibiotics

Antibiotics are used to fight bacteria causing infection. Infections are common in the lungs of people with cystic fibrosis, so antibiotics are an important part of regular care. Antibiotics come in three different forms: Oral antibiotics – liquids, tablets or capsules that…

Anti-Inflammatory Medication

Inflammation in the lungs of patients with CF is characterized by persistent and excessive neutrophil infiltration. Degradation of neutrophils in the airways leads to release of substantial amounts of DNA into sputum, thereby increasing secretion viscoelasticity. Several existing anti-inflammatory drugs,…

Bronchodilators

A bronchodilator is a medication that dilates the brocnhi and bronchioles (smaller airways), decreasing resistance in the respiratory airway and increasing airflow to the lungs. Bronchodilatators are used in various respiratory diseases and are part of the daily treatment of a…

Inhaled Medications

Inhaled medications are delivered with a nebulizer or puff (dry powder inhalator) in a mist of tiny droplets directly to the lungs, fostering penetration into the lungs. Inhaled drugs are commonly used in cystic fibrosis care because they reach the airways quickly and easily.…

Treating and preventing lung problems

CF is a complex disease and therapies must target problems in the airways and the digestive system. Thanks to clinical progress and research, people with cystic fibrosis (CF) have more therapy options to prevent and treat airway problems than ever before. There…

Drugs and treatment for other problems in CF

CF is a complex multi-organ disease and a complex treatment targetting the problems which may occur in multiple organs is needed to prevent, delay and treat symptoms. In this chapter on Disease management/Medication for treating CF you find more detailed information…

Get Involved

Start an article

  • 1
  • 2
  • 3
  • 4

Ask a question

Enter your question here:

Question of the month

What can this platform do to support patients and families better?: